Gene therapy, although in its infancy, is an important therapeutic modality of the future. In-silico approaches will be increasingly used at all stages of drug discovery and development for all modalities, and this is expected to radically impact the time taken and the success of new drug development. This investment may be seen as complementary to our investment in Mekonos, and will allow us to further learn about gene therapy and deepen our understanding of in-silico approaches to drug development.